The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Metastatic osteosarcoma at diagnosis: Prognostic factors and long‐term outcome—The French pediatric experience
Abstract
BACKGROUND: The objective of this report was to estimate long‐term outcome and prognostic factors in children and adolescents who presented with metastatic osteosarcoma at diagnosis. Patients were treated in six French pediatric oncology centers with surgery and multiagent chemotherapy, mainly with high‐dose methotrexate. Their medical records were reviewed retrospectively. METHODS: The medical records of patients who were treated for metastatic osteosarcoma from 1987 to 2000 were reviewed. Patients were treated with the chemotherapy regimens recommended for nonmetastatic disease in children (the French Society of Pediatric Oncology OS 87 and OS 94 protocols) or, in a few patients, with other chemotherapy regimens. Surgical excision of the primary tumor and, when possible, of all metastatic sites was performed based on a personalized assessment of each patient's situation. RESULTS: Seventy‐eight patients age < 20 years were treated. Forty‐six patients (59%) had only 1 metastatic site (35 to the lungs and 11 to bone). Twenty‐eight patients (36%) achieved a complete remission after combination chemotherapy and surgery. The event‐free survival and overall survival rates at 5 years were 14% and 19%, respectively. To date, 14 patients (18%) have remained alive with a median follow‐up of 112 months. Pretreatment features associated with a shorter event‐free survival in the multivariate analysis were metastasis to at least two organs and high alkaline phosphatase level. Patients with at least 1 of these poor prognostic factors had a 2.6% event‐free survival rate at 5 years despite treatment. CONCLUSIONS: The survival of patients with metastatic osteosarcoma were treated with conventional chemotherapy and surgery remained very poor. Patients should be classified into different prognostic groups and treated accordingly. New therapeutic approaches are warranted to improve the prognosis for patients with the most severe disease. Cancer 2005. © 2005 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Evaluation of survival data and two new rank order statistics arising in its consideration.
Mantel, N. (1966) · PubMed · Cited by 7,519
Spiess, P. E., Lee, A. K., Leibovici, D., Wang, X., Do, K., & Pisters, L. L. (2006) · Cancer · doi:10.1002/cncr.21979 · Cited by 1,930
Matthay, K. K., Villablanca, J. G., Seeger, R. C., Stram, D. O., Harris, R. E., Ramsay, N. K., Swift, P., Shimada, H., Black, C. T., Brodeur, G. M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910143411601 · Cited by 1,898
Rosen, G., Caparros, B., Huvos, A. G., Kosloff, C., Nirenberg, A., Cacavio, A., Marcove, R. C., Lane, J. M., Mehta, B., & Urban, C. (1982) · Cancer · doi:10.1002/1097-0142(19820315)49:6<1221::aid-cncr2820490625>3.0.co;2-e · Cited by 1,090
Kager, L., Zoubek, A., Pötschger, U., Kastner, U., Flege, S., Kempf-Bielack, B., Branscheid, D., Kotz, R., Salzer-Kuntschik, M., Winkelmann, W., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.08.132 · Cited by 934
Chemotherapy for nonmetastatic osteogenic sarcoma: the Memorial Sloan-Kettering experience.
Meyers, P. A., Heller, G., Healey, J., Huvos, A., Lane, J., Marcove, R., Applewhite, A., Vlamis, V, & Rosen, G. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.5 · Cited by 678
Expression of P-Glycoprotein in High-Grade Osteosarcomas in Relation to Clinical Outcome
Baldini, N., Scotlandi, K., Barbanti-Bròdano, G., Manara, M. C., Maurici, D., Bacci, G., Bertoni, F., Picci, P., Sottili, S., Campanacci, M., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511233332103 · Cited by 399
Ag, H., Rosen, G., & Marcove, R. C. (1977) · PubMed · Cited by 396
Osteogenic sarcoma with clinically detectable metastasis at initial presentation.
Meyers, P. A., Heller, G., Healey, J. H., Huvos, A., Applewhite, A., Sun, M., & LaQuaglia, M. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.449 · Cited by 390
Expression of HER2/erb B-2 Correlates With Survival in Osteosarcoma
Gorlick, R., Huvos, A. G., Heller, G., Aledo, A., Beardsley, G. P., Healey, J. H., & Meyers, P. A. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.9.2781 · Cited by 303
Adriamycin—an antitumor antibiotic in the treatment of neoplastic diseases
TAN, C. T. C., Etcubanas, E., Wollner, N., Rosen, G., Gilladoga, A. C., Showel, J. L., Murphy, M. L., & Krakoff, I. H. (1973) · Cancer · doi:10.1002/1097-0142(197307)32:1<9::aid-cncr2820320102>3.0.co;2-6 · Cited by 235
Goorin, A. M., Harris, M. B., Bernstein, M. L., Ferguson, W., Devidas, M., Siegal, G. P., Gebhardt, M. C., Schwartz, C. L., Link, M. P., & Grier, H. E. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.2.426 · Cited by 223
Kaste, S. C., Pratt, C. B., Cain, A. M., Jones-Wallace, D. J., & Rao, B. N. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19991015)86:8<1602::aid-cncr31>3.0.co;2-r · Cited by 215
Treatment of metastatic osteosarcoma at diagnosis: a Pediatric Oncology Group Study.
Harris, M. B., Gieser, P., Goorin, A. M., Ayala, A., Shochat, S. J., Ferguson, W. S., Holbrook, T., & Link, M. P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3641 · Cited by 185
Mechanisms of methotrexate resistance in osteosarcoma.
Guo, W., Healey, J. H., Meyers, P. A., Ladanyi, M., Huvos, A. G., Bertino, J. R., & Gorlick, R. G. (1999) · PubMed · Cited by 152
Schoenfeld, D., Cox, D. R., & Oakes, D. (1986) · Journal of the American Statistical Association · doi:10.2307/2289259 · Cited by 129
Zhou, H., Randall, R. L., Brothman, A. R., Maxwell, T. M., Coffin, C. M., & Goldsby, R. E. (2003) · Journal of Pediatric Hematology/Oncology · doi:10.1097/00043426-200301000-00007 · Cited by 125
Improved prognosis of children with osteosarcoma metastatic to the lung(s) at the time of diagnosis
Marina, N. M., Pratt, C. B., Rao, B. N., Shema, S. J., & Meyer, W. H. (1992) · Cancer · Cited by 118
Rosen, G., Huvos, A. G., Mosende, C., Beattie, E. J., Exelby, P. R., Caparros, B., & Marcove, R. C. (1978) · Cancer · doi:10.1002/1097-0142(197803)41:3<841::aid-cncr2820410310>3.0.co;2-z · Cited by 115
cis-Dichlorodiammineplatinum (II) in advanced osteogenic sarcoma.
Ochs, J. J., Freeman, A. I., Douglass, H. O., Ds, H., Mindell, E. R., & Lf, S. (1978) · PubMed · Cited by 108
Kilpatrick, S. E., Geisinger, K. R., King, T. S., Sciarrotta, J., Ward, W. G., Gold, S., & Bos, G. D. (2001) · Modern Pathology · doi:10.1038/modpathol.3880474 · Cited by 88
Gentet, J.-C., Brunat-Mentigny, M., Demaille, M. C., Pein, F., Avet-Loiseau, H., Berger, C., De Lumley, L., Pacquement, H., Schmitt, C., Sariban, E., et al. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(96)00439-x · Cited by 86 · cited 1×
“with known effectiveness against osteosarcoma, such as high-dose methotrexate,(9) doxorubicin,(10) cisplatinum,(11) etoposide, and high-dose ifosfamide.(12) Twenty-two patients were treated according to the French Society of Pediatric Oncology (SFOP) OS 87 protocol,(13) 39 patients were treated according to the OS 94…”
Self-citationLoss of p16INK4a expression correlates with decreased survival in pediatric osteosarcomas
Maitra, A., Roberts, H., Weinberg, A. G., & Geradts, J. (2001) · International Journal of Cancer · doi:10.1002/1097-0215(20010120)95:1<34::aid-ijc1006>3.0.co;2-v · Cited by 72
Ferguson, W. S., Harris, M. B., Goorin, A. M., Gebhardt, M. C., Link, M. P., Shochat, S. J., Siegal, G. P., Devidas, M., & Grier, H. E. (2001) · The American journal of pediatric hematology/oncology · doi:10.1097/00043426-200108000-00004 · Cited by 72
Jayet, H., & Moreau, A. (1991) · Journal of Econometrics · doi:10.1016/0304-4076(91)90041-b · Cited by 56
Multifocal synchronous osteosarcoma: The Scottish bone tumour registry experience
Jones, R. D., Reid, R., Balakrishnan, G., et al. (1993) · Medical and Pediatric Oncology · doi:10.1002/mpo.2950210206 · Cited by 28
Pacquement, H., Kahfa, C., Fagnou, C., Demaille, M. C., Brunat-Mentigny, M., Sariban, E., Pérel, Y., & Zucker, J. M. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)85082-4 · Cited by 8
Self-citation
Cited by
Osteosarcoma: a comprehensive review
Misaghi, A., Goldin, A., Awad, M., & Kulidjian, A. A. (2018) · SICOT-J · doi:10.1051/sicotj/2017028 · Cited by 517
Lindsey, B. A., Markel, J. E., & Kleinerman, E. S. (2017) · Rheumatology and Therapy · doi:10.1007/s40744-016-0050-2 · Cited by 487
Dog models of naturally occurring cancer
Rowell, J. L., McCarthy, D. O., & Alvarez, C. E. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2011.02.004 · Cited by 384
Duchman, K. R., Gao, Y., & Miller, B. J. (2015) · Cancer Epidemiology · doi:10.1016/j.canep.2015.05.001 · Cited by 305
Metastatic osteosarcoma: a challenging multidisciplinary treatment
Meazza, C., & Scanagatta, P. (2016) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2016.1168697 · Cited by 298
Metadata
- Authors
- Mialou, V., Philip, T., Kalifa, C., Perol, D., Gentet, J., Marec‐Berard, P., Pacquement, H., Chastagner, P., Defaschelles, A., & Hartmann, O.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2005-07-13
- Volume
- 104
- Issue
- 5
- Pages
- 1100-1109
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2046548272
- Cited by
- 286
- References
- 28
- FWCI
- 4.69
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.